CO2021016003A2 - Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b - Google Patents
Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2bInfo
- Publication number
- CO2021016003A2 CO2021016003A2 CONC2021/0016003A CO2021016003A CO2021016003A2 CO 2021016003 A2 CO2021016003 A2 CO 2021016003A2 CO 2021016003 A CO2021016003 A CO 2021016003A CO 2021016003 A2 CO2021016003 A2 CO 2021016003A2
- Authority
- CO
- Colombia
- Prior art keywords
- substituted pyrazolo
- glun2b receptor
- receptor modulators
- glun2b
- pyridine amides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Pirazolo-piridinas sustituidas como ligandos del receptor GluN2B. Tales compuestos pueden usarse en la modulación del receptor GluN2B y en composiciones farmacéuticas y métodos para el tratamiento de estados de enfermedad, trastornos, y afecciones mediadas por la actividad del receptor GluN2B.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962861656P | 2019-06-14 | 2019-06-14 | |
PK35020 | 2020-06-03 | ||
ARP200101623A AR119125A1 (es) | 2019-06-14 | 2020-06-09 | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b |
PCT/EP2020/066392 WO2020249792A1 (en) | 2019-06-14 | 2020-06-12 | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021016003A2 true CO2021016003A2 (es) | 2021-12-10 |
Family
ID=73781829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0016003A CO2021016003A2 (es) | 2019-06-14 | 2021-11-26 | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b |
Country Status (21)
Country | Link |
---|---|
US (2) | US11618750B2 (es) |
EP (1) | EP3983075A1 (es) |
JP (1) | JP2022536522A (es) |
KR (1) | KR20220024511A (es) |
CN (1) | CN113993868A (es) |
AU (1) | AU2020290016A1 (es) |
BR (1) | BR112021024856A2 (es) |
CA (1) | CA3142996A1 (es) |
CL (1) | CL2021003277A1 (es) |
CO (1) | CO2021016003A2 (es) |
CR (1) | CR20210580A (es) |
DO (1) | DOP2021000251A (es) |
EC (1) | ECSP21090478A (es) |
IL (1) | IL288859A (es) |
JO (1) | JOP20210328A1 (es) |
MA (1) | MA56196A (es) |
MX (1) | MX2021015506A (es) |
PE (1) | PE20220386A1 (es) |
SG (1) | SG11202112407PA (es) |
TW (1) | TW202112774A (es) |
WO (1) | WO2020249792A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
CA3142996A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
CN113993583A (zh) | 2019-06-14 | 2022-01-28 | 詹森药业有限公司 | 取代的吡唑并[4,3-b]吡啶及其作为GLUN2B受体调节剂的用途 |
MX2021015503A (es) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica Nv | Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b. |
KR20220020915A (ko) | 2019-06-14 | 2022-02-21 | 얀센 파마슈티카 엔.브이. | GluN2B 수용체 조절제로서의 피라진 카르바메이트 및 이들의 용도 |
JP2022538774A (ja) | 2019-06-14 | 2022-09-06 | ヤンセン ファーマシューティカ エヌ.ベー. | ピリジンカルバメート及びglun2b受容体調節因子としてのそれらの使用 |
CN114008052A (zh) | 2019-06-14 | 2022-02-01 | 詹森药业有限公司 | 取代的吡唑并-吡嗪以及它们作为GluN2B受体调节剂的用途 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9407447D0 (en) | 1994-04-14 | 1994-06-08 | Glaxo Group Ltd | Chemical compounds |
CA2262502C (en) | 1996-07-31 | 2002-11-26 | Nikken Chemicals Co., Ltd. | 6-phenyltetrahydro-1,3-oxazin-2-one derivatives and pharmaceutical composition containing the same |
WO2002000629A1 (en) | 2000-06-26 | 2002-01-03 | Merck & Co., Inc. | Iminopyrimidine nmda nr2b receptor antagonists |
US6610723B2 (en) | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
IL164187A0 (en) | 2002-03-28 | 2005-12-18 | Eisai Co Ltd | 7-Azaindole derivatives and pharmaceutical compositions containing the same |
US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
WO2003101968A1 (fr) | 2002-05-31 | 2003-12-11 | Eisai Co., Ltd. | Compose de pyrazole et composition medicinale le contenant |
EP1720860A1 (en) | 2004-02-18 | 2006-11-15 | AstraZeneca AB | Triazole compounds and their use as metabotropic glutamate receptor antagonists |
EP1805142A4 (en) | 2004-09-23 | 2009-06-10 | Reddy Us Therapeutics Inc | PYRIDINE-BASED COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME |
JP5275794B2 (ja) * | 2005-06-22 | 2013-08-28 | ケモセントリックス,インコーポレイティド | アザインダゾール化合物および使用方法 |
US7807704B2 (en) | 2006-03-30 | 2010-10-05 | Chemocentryx, Inc. | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
TWI443090B (zh) | 2007-05-25 | 2014-07-01 | Abbvie Deutschland | 作為代謝性麩胺酸受體2(mglu2 受體)之正向調節劑之雜環化合物 |
WO2009004430A1 (en) | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
JPWO2009028543A1 (ja) | 2007-08-30 | 2010-12-02 | 武田薬品工業株式会社 | 置換ピラゾール誘導体 |
US20100249164A1 (en) | 2007-10-31 | 2010-09-30 | Renger John J | Modulation of sleep with nr2b receptor antagonists |
WO2009118187A1 (en) | 2008-03-27 | 2009-10-01 | Evotec Neurosciences Gmbh | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
EP2298731A4 (en) | 2008-06-25 | 2011-09-21 | Takeda Pharmaceutical | AMIDE COMPOUND |
RU2478636C2 (ru) | 2008-08-05 | 2013-04-10 | Дайити Санкио Компани, Лимитед | ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДИН-2-ОНА, ОБЛАДАЮЩИЕ mTOR ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ |
US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
AU2009304293B2 (en) | 2008-10-16 | 2012-04-26 | Addex Pharma S.A. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
ES2554375T3 (es) | 2008-11-25 | 2015-12-18 | University Of Rochester | Inhibidores de las MLK y métodos de uso |
WO2010108187A2 (en) | 2009-03-20 | 2010-09-23 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
WO2011022348A1 (en) | 2009-08-18 | 2011-02-24 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid amide hydrolase |
US8765784B2 (en) | 2010-06-09 | 2014-07-01 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of MGLUR2 |
WO2011158108A2 (en) * | 2010-06-16 | 2011-12-22 | Purdue Pharma L.P. | Aryl substituted indoles and the use thereof |
EP2669270B1 (en) * | 2011-01-28 | 2018-01-03 | Sato Pharmaceutical Co., Ltd. | Indole-related compounds as urat1 inhibitors |
JP2012188363A (ja) | 2011-03-09 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | アザベンゾイミダゾロン誘導体 |
DK2570415T3 (en) | 2011-09-19 | 2015-11-23 | Sanofi Sa | N- [4- (1H-pyrazolo [3,4-b] pyrazin-6-yl) phenyl] sulfonamides and their use as medicaments |
WO2013060029A1 (en) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp | Allosteric modulators of metabotropic glutamate receptors |
US9434743B2 (en) | 2012-03-02 | 2016-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
WO2014124651A1 (en) | 2013-02-15 | 2014-08-21 | Københavns Universitet | Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists |
JP2016516710A (ja) | 2013-03-13 | 2016-06-09 | アッヴィ・インコーポレイテッド | ピリジン系cdk9キナーゼ阻害薬 |
RU2680100C9 (ru) | 2013-03-15 | 2019-04-18 | Плексксикон Инк. | Гетероциклические соединения и их применения |
CN109939113B (zh) | 2013-06-21 | 2022-02-15 | 恒翼生物医药科技(上海)有限公司 | 双环溴结构域抑制剂 |
AU2014296261B2 (en) | 2013-07-31 | 2018-11-15 | Merck Patent Gmbh | Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof |
DK3180315T3 (da) | 2014-08-15 | 2020-04-06 | Janssen Pharmaceuticals Inc | Pyrazoler |
ES2791186T3 (es) | 2014-08-15 | 2020-11-03 | Janssen Pharmaceuticals Inc | Triazoles como inhibidores de receptores NR2B |
WO2016081649A1 (en) | 2014-11-18 | 2016-05-26 | Emory University | Thieno[2,3-d]pyrimidin-4-one derivatives as nmdar modulators and uses related thereto |
MA41803A (fr) | 2015-03-24 | 2018-01-30 | Almirall Sa | Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques |
MA42397B1 (fr) | 2015-07-09 | 2020-02-28 | Janssen Pharmaceutica Nv | 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b |
BR112018016329A2 (pt) | 2016-02-10 | 2018-12-18 | Janssen Pharmaceutica Nv | 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b |
TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
JP7252908B2 (ja) | 2017-06-14 | 2023-04-05 | トレベナ・インコーポレイテッド | S1p1活性を調節するための化合物およびその使用法 |
US10766893B2 (en) | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
JP7346441B2 (ja) | 2018-04-04 | 2023-09-19 | ヤンセン ファーマシューティカ エヌ.ベー. | 置換ピリジン及びピリミジン並びにglun2b受容体調節物質としてのそれらの使用 |
CN110294756A (zh) | 2019-06-04 | 2019-10-01 | 广州市原子高科同位素医药有限公司 | GluN2B亚基靶向型中枢神经系统正电子示踪剂及其制备 |
CN114008052A (zh) | 2019-06-14 | 2022-02-01 | 詹森药业有限公司 | 取代的吡唑并-吡嗪以及它们作为GluN2B受体调节剂的用途 |
CA3142996A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
CN113993583A (zh) | 2019-06-14 | 2022-01-28 | 詹森药业有限公司 | 取代的吡唑并[4,3-b]吡啶及其作为GLUN2B受体调节剂的用途 |
MX2021015503A (es) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica Nv | Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b. |
JP2022538774A (ja) | 2019-06-14 | 2022-09-06 | ヤンセン ファーマシューティカ エヌ.ベー. | ピリジンカルバメート及びglun2b受容体調節因子としてのそれらの使用 |
KR20220020915A (ko) | 2019-06-14 | 2022-02-21 | 얀센 파마슈티카 엔.브이. | GluN2B 수용체 조절제로서의 피라진 카르바메이트 및 이들의 용도 |
-
2020
- 2020-06-12 CA CA3142996A patent/CA3142996A1/en active Pending
- 2020-06-12 BR BR112021024856A patent/BR112021024856A2/pt unknown
- 2020-06-12 KR KR1020227001089A patent/KR20220024511A/ko unknown
- 2020-06-12 MX MX2021015506A patent/MX2021015506A/es unknown
- 2020-06-12 AU AU2020290016A patent/AU2020290016A1/en active Pending
- 2020-06-12 PE PE2021001941A patent/PE20220386A1/es unknown
- 2020-06-12 EP EP20737362.2A patent/EP3983075A1/en active Pending
- 2020-06-12 CN CN202080043675.8A patent/CN113993868A/zh active Pending
- 2020-06-12 MA MA056196A patent/MA56196A/fr unknown
- 2020-06-12 JP JP2021573898A patent/JP2022536522A/ja active Pending
- 2020-06-12 CR CR20210580A patent/CR20210580A/es unknown
- 2020-06-12 JO JOP/2021/0328A patent/JOP20210328A1/ar unknown
- 2020-06-12 WO PCT/EP2020/066392 patent/WO2020249792A1/en unknown
- 2020-06-12 US US16/899,823 patent/US11618750B2/en active Active
- 2020-06-12 TW TW109119835A patent/TW202112774A/zh unknown
- 2020-06-12 SG SG11202112407PA patent/SG11202112407PA/en unknown
-
2021
- 2021-11-26 CO CONC2021/0016003A patent/CO2021016003A2/es unknown
- 2021-12-02 DO DO2021000251A patent/DOP2021000251A/es unknown
- 2021-12-09 IL IL288859A patent/IL288859A/en unknown
- 2021-12-09 CL CL2021003277A patent/CL2021003277A1/es unknown
- 2021-12-14 EC ECSENADI202190478A patent/ECSP21090478A/es unknown
-
2022
- 2022-10-14 US US17/966,696 patent/US20230151006A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MA56196A (fr) | 2022-04-20 |
WO2020249792A1 (en) | 2020-12-17 |
US11618750B2 (en) | 2023-04-04 |
CA3142996A1 (en) | 2020-12-17 |
JP2022536522A (ja) | 2022-08-17 |
IL288859A (en) | 2022-02-01 |
US20230151006A1 (en) | 2023-05-18 |
SG11202112407PA (en) | 2021-12-30 |
ECSP21090478A (es) | 2022-01-31 |
PE20220386A1 (es) | 2022-03-18 |
US20210017168A1 (en) | 2021-01-21 |
CN113993868A (zh) | 2022-01-28 |
MX2021015506A (es) | 2022-02-10 |
BR112021024856A2 (pt) | 2022-01-18 |
DOP2021000251A (es) | 2022-04-18 |
CR20210580A (es) | 2022-01-31 |
KR20220024511A (ko) | 2022-03-03 |
CL2021003277A1 (es) | 2022-08-19 |
AU2020290016A1 (en) | 2022-01-06 |
JOP20210328A1 (ar) | 2023-01-30 |
TW202112774A (zh) | 2021-04-01 |
EP3983075A1 (en) | 2022-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP21090478A (es) | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b | |
CL2021003257A1 (es) | Pirazolo-piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b. | |
CL2019000882A1 (es) | Sustituto de 1h-imidazo[4,5-b]piridina-2(3h)-ones y sus uso como moduladores de receptor glun2b. | |
CO2021007993A2 (es) | Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina | |
MX2018000352A (es) | 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b. | |
BR112018016329A2 (pt) | 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b | |
MX2021015500A (es) | Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. | |
EA201591403A1 (ru) | Спиролактамные модуляторы рецептора nmda и их применение | |
MX2021000848A (es) | Compuestos y sus usos para modular la hemoglobina. | |
NZ737399A (en) | Ccr2 modulators | |
CR20170250A (es) | TETRAHIDRO-PIRIDO[3,4-b]INDOLES MODULADORES DE RECEPTORES DE ESTRÓGENOS Y USOS DE LOS MISMOS | |
CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
MX2015011769A (es) | Compuestos y sus usos para modular la hemoglobina. | |
MX2015011445A (es) | Compuestos y usos de estos para la modulacion de la hemoglobina. | |
CL2020001990A1 (es) | Moduladores del receptor nmda espiro-lactama y usos de los mismos. (hna. 1991-20) | |
MX2021015508A (es) | Carbamatos de piridina y su uso como moduladores del receptor glun2b. | |
CO2017012622A2 (es) | Moduladores alostéricos positivos del receptor muscarínico m2 | |
MX2021015511A (es) | Carbamatos de pirazina y sus usos como moduladores del receptor glun2b. | |
EP4219507A3 (en) | Thienopyrimidinone nmda receptor modulators and uses thereof | |
UY34991A (es) | Inhibidores de la beta-secretasa | |
CL2016002321A1 (es) | Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios. | |
BR112016028614A8 (pt) | novos agonistas de ep4, composição farmacêutica compreendendo os mesmos e seu uso | |
EA201992051A1 (ru) | Агонисты фарнезоидного x-рецептора и их применение | |
AR102952A1 (es) | Tratamiento de condiciones oculares usando células progenitoras |